Neha Mehta-Shah
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A) Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.
Year:
2025
Regulating Hippo. A, Diagram of pathways that regulate Hippo signaling. Identified SMGs are shown in red; genes mutated in at least one non-hypermutated sample are shown in yellow; genes only mutated in the hypermutated sample (HL-513) are shown in orange. The gene mutation frequency across the cohort is shown as a percent. The pathways labeled in green indicate larger pathways not shown in this diagram. B, The total number and type of mutation observed are shown in the inset bar chart. C, Lolliplot of CDH5 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom. D, Lolliplot of mutations identified at GNA13 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom.
Year:
2025
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7, novel stop gain mutations in IL4R , and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3 ). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL. Significance: Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
Year:
2025
Purpose: Proliferation of T-follicular helper (T FH ) CD4 + T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by T FH , representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS + cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT), and recommended phase II dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01–3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29–86) and the median prior lines of therapies was 3 (1–16). Most common grade 3 or 4 adverse events were decreased CD4 + T cells (57%), lymphopenia (22%), anemia (13%), and infusion-related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4 + ICOS + T cells reflecting its effects on T FH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS + T lymphocytes.
Year:
2025
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A)Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.
Year:
2024
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A)Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.
Year:
2024
Purpose: Proliferation of T-follicular helper (T FH ) CD4+ T-cells is a postulated pathogenic mechanism for T-cell non-Hodgkin’s lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by T FH , representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT) and recommended phase 2 dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01 mg/kg to 3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29 - 86) and the median prior lines of therapies was 3 (1 - 16). Most common grade 3 or 4 adverse events were decreased CD4+ T-cells (57%), lymphopenia (22%), anemia (13%), and infusion related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4+ICOS+ T cells reflecting its effects on T FH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.
Year:
2024
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL). Outcomes for the majority of patients with PTCL are poor and treatment approaches have been relatively uniform using CHOP based therapy. For example, large registry studies consistently demonstrate 5-year overall survival (OS) of approximately 30-40%. However, as our understanding of the biology underpinning the heterogeneity of PTCL improves, and as treatments specifically for PTCL are developed, risk stratification has become a more relevant question. Tools including positron emission tomography-computed tomography (PET-CT) and minimal residual disease (MRD) monitoring offer the potential for dynamic risk stratification. In this review, we will first summarize registry data describing outcomes in the most common subtypes of PTCL - PTCL not otherwise specified (PTCL-NOS), nodal T-follicular helper cell lymphoma including angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). We will describe current clinically based prognostic indices validated in PTCL and then highlight emerging tools for prognostication including novel molecular biomarkers, imaging-based metrics, and MRD dynamics.
Year:
2023
Collaborators (20)
Robert Fulton
Assistant Professor
Washington University in St. Louis
Todd A. Fehniger
Professor
Washington University School of Medicine
Obi Griffith
Professor
Washington University in St. Louis
Kilannin Krysiak
Associate Professor
Washington University in St. Louis
Nancy Bartlett
Koman Professor of Medical Oncology in Medicine
Washington University in St. Louis
Joseph Tuscano
Professor
University of California Davis Comprehensive Cancer Center
David A. Russler-Germain
Washington University School of Medicine
Julio Chavez
Associate Professor
Moffitt Cancer Center
Lillian L. Siu
University Health Network
Jonathan E. Brammer
Associate Professor, T-Cell Lymphomas
Ohio State University
Sonali M. Smith
University of Chicago
Harsh Shah
Clinical Assistant Professor
Huntsman Cancer Institute
Zachary Skidmore
Senior Scientist
Washington University in St. Louis
Francine Foss
Yale University
Anca Prica
-
Eric J. Duncavage
Professor/Director of Molecular Oncology
Washington University School of Medicine
Malachi Griffith
Professor
Washington University in St. Louis
Jasmine Zain
Attending
Memorial Sloan Kettering Cancer Center
Christopher Miller
Associate Professor
Washington University in St. Louis
Felicia Gomez
Assistant Professor (tenure track)
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.